PROPANC BIOPHARMA, INC. Total Liabilities and Equity
PROPANC BIOPHARMA, INC. (PPCB) had Total Liabilities and Equity of $14.33 million as of 2026-03-31, per its S-1 filed 2026-07-17.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-07-17
- 2026-03-31: Liabilities and Equity $14.33M.
- 2025-12-31: Liabilities and Equity $15.11M.
- 2025-09-30: Liabilities and Equity $17.98M.
- 2025-06-30: Liabilities and Equity $19.63M.
| Period end | Liabilities and Equity |
|---|---|
| 2026-03-31 | $14.33M S-1 · filed 2026-07-17 |
| 2025-12-31 | $15.11M S-1 · filed 2026-04-10 |
| 2025-09-30 | $17.98M 10-Q · filed 2025-11-14 |
| 2025-06-30 | $19.63M S-1 · filed 2026-07-17 |
| 2025-03-31 | $22.53M 10-Q · filed 2025-05-15 |
| 2024-12-31 | $78.53K 10-Q · filed 2025-02-14 |
| 2024-09-30 | $63.64K 10-Q · filed 2024-11-14 |
| 2024-06-30 | $72.36K S-1 · filed 2026-07-17 |
| 2024-03-31 | $37.34K 10-Q · filed 2024-05-15 |
| 2023-12-31 | $241.91K 10-Q · filed 2024-02-20 |
| 2023-09-30 | $180.37K 10-Q · filed 2023-11-14 |
| 2023-06-30 | $60.33K 10-K · filed 2024-09-30 |
| 2023-03-31 | $143.74K 10-Q · filed 2023-05-15 |
| 2022-12-31 | $108.02K 10-Q · filed 2023-02-10 |
| 2022-09-30 | $94.25K 10-Q · filed 2022-11-14 |
| 2022-06-30 | $81.65K 10-K · filed 2023-09-28 |
| 2022-03-31 | $169.46K 10-Q · filed 2022-05-16 |
| 2021-12-31 | $110.18K 10-Q · filed 2022-02-14 |
| 2021-09-30 | $62.16K 10-Q · filed 2021-11-12 |
| 2021-06-30 | $13.10K 10-K · filed 2022-09-28 |
| 2021-03-31 | $28.04K 10-Q · filed 2021-05-14 |
| 2020-12-31 | $40.62K 10-Q · filed 2021-02-12 |
| 2020-09-30 | $77.55K 10-Q · filed 2020-11-16 |
| 2020-06-30 | $98.52K 10-K · filed 2021-09-28 |
| 2020-03-31 | $63.94K 10-Q · filed 2020-05-15 |
| 2019-12-31 | $65.42K 10-Q · filed 2020-02-14 |
| 2019-09-30 | $197.66K 10-Q · filed 2019-11-14 |
| 2019-06-30 | $101.65K 10-K · filed 2020-10-01 |
| 2019-03-31 | $259.92K 10-Q · filed 2019-05-15 |
| 2018-12-31 | $712.60K 10-Q · filed 2019-02-14 |
| 2018-09-30 | $82.78K 10-Q · filed 2018-11-13 |
| 2018-06-30 | $71.39K 10-K · filed 2019-10-15 |
| 2018-03-31 | $110.75K 10-Q · filed 2018-05-10 |
| 2017-12-31 | $129.08K 10-Q · filed 2018-02-09 |
| 2017-09-30 | $162.51K 10-Q · filed 2017-11-09 |
| 2017-06-30 | $95.07K 10-K · filed 2018-09-17 |
| 2017-03-31 | $44.79K 10-Q · filed 2017-05-08 |
| 2016-12-31 | $135.84K 10-Q · filed 2017-02-14 |
| 2016-09-30 | $181.40K 10-Q · filed 2016-11-10 |
| 2016-06-30 | $379.14K 10-K · filed 2017-09-28 |
| 2016-03-31 | $1.62M 10-Q · filed 2016-05-16 |
| 2015-12-31 | $1.51M 10-Q · filed 2016-02-16 |
| 2015-09-30 | $305.12K 10-Q · filed 2015-11-16 |
| 2015-06-30 | $627.07K 10-K · filed 2016-09-28 |
| 2015-03-31 | $309.62K 10-Q · filed 2015-05-15 |
| 2014-12-31 | $52.94K 10-Q · filed 2015-02-17 |
| 2014-09-30 | $51.57K 10-Q · filed 2014-11-19 |
| 2014-06-30 | $113.75K 10-K · filed 2015-09-30 |
| 2014-03-31 | $40.00 10-Q · filed 2014-05-20 |
| 2013-12-31 | $11.92K 10-Q · filed 2014-02-14 |
| 2013-09-30 | $38.72K 10-Q · filed 2013-11-14 |
| 2013-06-30 | $1.75K 10-K · filed 2014-10-14 |
| 2013-03-31 | $4.14K 10-Q · filed 2013-05-20 |
| 2012-12-31 | $12.30K 10-Q · filed 2013-02-20 |
| 2012-09-30 | $27.09K 10-Q · filed 2012-11-19 |
| 2012-06-30 | $46.27K 10-K · filed 2013-10-15 |
| 2012-03-31 | $2.16M 10-Q · filed 2012-05-21 |
| 2011-12-31 | $4.87M 10-Q/A · filed 2012-03-07 |
| 2011-06-30 | $10.81M 10-K · filed 2012-10-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |